monica crugnola
monica crugnola
Unknown affiliation
Verified email at
TitleCited byYear
Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
C Cesana, C Klersy, L Barbarano, AM Nosari, M Crugnola, E Pungolino, ...
Journal of Clinical Oncology 20 (6), 1625-1634, 2002
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
N Giuliani, F Morandi, S Tagliaferri, M Lazzaretti, S Bonomini, M Crugnola, ...
Blood, The Journal of the American Society of Hematology 110 (1), 334-338, 2007
Survival of elderly patients with acute myeloid leukemia
A Pulsoni, L Pagano, R Latagliata, M Casini, R Cerri, M Crugnola, ...
haematologica 89 (3), 296-302, 2004
CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival
N Giuliani, S Bonomini, P Romagnani, M Lazzaretti, F Morandi, S Colla, ...
Haematologica 91 (11), 1489-1497, 2006
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
L Arcaini, M Paulli, S Burcheri, A Rossi, M Spina, F Passamonti, M Lucioni, ...
British journal of haematology 136 (2), 301-304, 2007
Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients
S Colla, F Morandi, M Lazzaretti, R Rizzato, P Lunghi, S Bonomini, ...
Leukemia 19 (12), 2166-2176, 2005
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
S Monfardini, SML Aversa, V Zoli, L Salvagno, A Bianco, R Bordonaro, ...
Annals of oncology 16 (8), 1352-1358, 2005
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease
K Todoerti, G Lisignoli, P Storti, L Agnelli, F Novara, C Manferdini, ...
Experimental hematology 38 (2), 141-153, 2010
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia
R Latagliata, M Breccia, C Fava, F Stagno, M Tiribelli, L Luciano, ...
Hematological oncology 31 (2), 103-109, 2013
Short-term ex vivo expansion sustains the homing-related properties of umbilical cord blood hematopoietic stem and progenitor cells
QL Zhai, LG Qiu, Q Li, HX Meng, JL Han, RH Herzig, ZC Han
haematologica 89 (3), 265-273, 2004
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG
A Olivieri, G Santini, C Patti, T Chisesi, C De Souza, A Rubagotti, ...
Annals of oncology 16 (12), 1941-1948, 2005
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis
F Palandri, R Latagliata, N Polverelli, A Tieghi, M Crugnola, B Martino, ...
Leukemia 29 (6), 1344-1349, 2015
Differences among young adults, adults and elderly chronic myeloid leukemia patients
F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ...
Annals of Oncology 26 (1), 185-192, 2015
The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia …
F Palandri, F Castagnetti, I Iacobucci, G Martinelli, M Amabile, G Gugliotta, ...
haematologica 95 (8), 1415-1419, 2010
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
M Montillo, A Tedeschi, VB Petrizzi, F Ricci, M Crugnola, M Spriano, ...
Blood, The Journal of the American Society of Hematology 118 (15), 4079-4085, 2011
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients
M Breccia, F Efficace, S Sica, E Abruzzese, M Cedrone, D Turri, M Gobbi, ...
Leukemia research 39 (10), 1055-1059, 2015
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
A Palumbo, A Larocca, P Falco, G Sanpaolo, AP Falcone, V Federico, ...
Leukemia 24 (5), 1037-1042, 2010
e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
S Colla, G Sammarelli, S Voltolini, M Crugnola, P Sebastio, N Giuliani
Haematologica 89 (5), 611-613, 2004
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study
R Latagliata, D Ferrero, A Iurlo, F Cavazzini, F Castagnetti, E Abruzzese, ...
Drugs & aging 30 (8), 629-637, 2013
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
S Soverini, C De Benedittis, KM Polakova, J Linhartova, F Castagnetti, ...
Oncotarget 7 (16), 21982, 2016
The system can't perform the operation now. Try again later.
Articles 1–20